4) Mettl3 ablation stabilized key genes involved in liver lipid and glucose metabolism, and particularly elevated the mRNA stability of an important regulator of hepatic lipid and glucose metabolism, Lpin1. Collectively, our findings demonstrate the critical roles for Mettl3-mediated m6A modification in HFD-induced liver metabolic disorders and hepatogenous diabetes, supporting that m6A might be a potential therapeutic and diagnostic target for hepatic diseases. This evidence concerns the gene LPIN1 and liver disorder.